Work

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms

Year: 2018

Type: article

Study design: Clinical Trial

Source: Leukemia Research

DOI: 10.1016/j.leukres.2018.06.014

Authors: J. Berdeja, F. Palandri, M.R. Baer, D. Quick, J.J. Kiladjian, G. Martinelli, A. Verma, O. Hamid, R. Walgren, C. Pitou, P.L. Li, A.T. Gerds

Institutions: Tennessee Oncology, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Inserm, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, Centre d'Investigation Clinique Saint-Louis, Albert Einstein College of Medicine, Montefiore Medical Center, Eli Lilly (United States), Cleveland Clinic

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Eli Lilly and Company, World Health Organization

OpenAlex ID: W2810959879

FWCI: 3.819

Cites: 27

Cited by: 54

Related to: 10